Patent US4740365A successfully refreshed from Google Patents.
US4740365A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained-release preparation applicable to mucous membrane in oral cavity
Assignee: Toyobo Co Ltd
•
Filing: 1985-04-05
•
Granted: 1988-04-26
•
Expires: 2005-04-05
Abstract
Abstract A sustained-release preparation applicable to mucous membrane in oral cavity which comprises an active ingredient and a mixture of a polymer component (A) comprising one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether and a polymer component (B) comprising one or more polymers selected from polyacrylic acid and a salt thereof, said polymer component (A) and polymer component (B) being contained in a ratio of 95:5 to 5:95 by weight, and optionally in admixture with conventional carrier and additives. Said preparation may be formed in the form of a two-layer preparation with a layer comprising an active ingredient and one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether and optionally in admixture with conventional carrier and additives. The preparation can easily be adhered to mucous membrane within oral cavity and maintained for a long period of time and the medicament (e.g. nifedipine) contained therein is released into saliva continuously to exhibit the activity effectively.
Inventors
- 👤 Keiji Yukimatsu
- 👤 Munetaka Kakumoto
- 👤 Yoshihisa Yasuda
- 👤 Junko Tsujimoto
- 👤 Masae Sogabe
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 21:45
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/006; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
93 words
A sustained-release preparation applicable to mucous membrane in oral cavity, which comprises an active ingredient and a mixture of a polymer component (A) comprising one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a pharmaceutically acceptable salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether and a polymer component (B) comprising one or more polymers selected from polyacrylic acid and a pharmaceutically acceptable salt thereof, said polymer component (A) and polymer component (B) being contained in a ratio of 95:5 to 5:95 by weight.
Claim 2
Dependent Claim
93 words
A sustained-release preparation applicable to mucous membrane in oral cavity, which comprises an active ingredient and a mixture of a polymer component (A) comprising one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a pharmaceutically acceptable salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether and a polymer component (B) comprising one or more polymers selected from polyacrylic acid and a pharmaceutically acceptable salt thereof, said polymer component (A) and polymer component (B) being contained in a ratio of 95:5 to 5:95 by weight.
Claim 3
Dependent Claim
27 words
The sustained-release preparation according to claim 1, wherein the active ingredient is nifedipine in the form of a solid solution in polyvinylpyrrolidone of the polymer component (A).
Claim 4
Dependent Claim
26 words
The sustained-release preparation according to claim 2, wherein the polyvinylpyrrolidone used for the solid solution has a molecular weight of 1×10 4 to 1×10 5 .
Claim 5
Dependent Claim
168 words
A sustained-release preparation applicable to mucous membrane in oral cavity, which comprises a layer (I) comprising an active ingredient and one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a pharmaceutically acceptable salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether and optionally in admixture with conventional carrier and additives, said polymer being contained in an amount of not less than 20% by weight based on the whole weight of the layer (I), and a layer (II) comprising an active ingredient and a mixture of a polymer component (A) comprising one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a pharmaceutically acceptable salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether and a polymer component (B) comprising one or more polymers selected from polyacrylic acid and a pharmaceutically acceptable salt thereof, said polymer component (A) and polymer component (B) being contained in a ratio of 95:5 to 5:95 by weight.
Claim 6
Dependent Claim
168 words
A sustained-release preparation applicable to mucous membrane in oral cavity, which comprises a layer (I) comprising an active ingredient and one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a pharmaceutically acceptable salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether and optionally in admixture with conventional carrier and additives, said polymer being contained in an amount of not less than 20% by weight based on the whole weight of the layer (I), and a layer (II) comprising an active ingredient and a mixture of a polymer component (A) comprising one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a pharmaceutically acceptable salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether and a polymer component (B) comprising one or more polymers selected from polyacrylic acid and a pharmaceutically acceptable salt thereof, said polymer component (A) and polymer component (B) being contained in a ratio of 95:5 to 5:95 by weight.
Claim 7
Dependent Claim
88 words
The sustained-release preparation according to claim 4, wherein the layer (I) comprises a solid solution of nifedipine in polyvinylpyrrolidone and a pharmaceutically acceptable carrier, said polyvinylpyrrolidone being contained in an amount of 20 to 80% by weight based on the whole weight of the layer (I), and the layer (II) comprises a solid solution of nifedipine in polyvinylpyrrolidone and polyacrylic acid and/or a pharmaceutically acceptable salt thereof, said solid solution and polyacrylic acid and/or a salt thereof being contained in a ratio of 95:5 to 5:95 by weight.
Claim 8
Dependent Claim
45 words
The sustained-release preparation according to claim 5, wherein the polyvinylpyrrolidone used for the layer (I) has a molecular weight of 1×10 4 to 1×10 5 , and the polyvinylpyrrolidone used for the layer (II) has a molecular weight of 1×10 5 to 4×10 5 .
Claim 9
Dependent Claim
63 words
The sustained-release preparation of claim 1 wherein said active ingredient and said polymer components (A) and (B) are in admixture with at least one additive ingredient selected from the group consisting of excipients, lubricants, binding agents, and flavors and seasonings, said additive ingredients being incorporated in an amount of not more than 40% by weight based on the total weight of the preparation.
Claim 10
Dependent Claim
53 words
The sustained-release preparation of claim 7 wherein said at least one additive ingredient is selected from the group consisting of talc, stearic acid, salts of stearic acid, waxes, starches, dextrin, tragacanth, gelatin, hydroxypropyl cellulose, crystalline cellulose, lactose, mannitol, sorbitol, anhydrous calcium phosphate, citric acid, fumaric acid, tartaric acid, menthol and citrus fruit flavors.
References Cited (Backward Citations)
US4412986A
Cited
US4292299A
Cited
US4250163A
Cited
US4343789A
Cited
US4404183A
Cited
US4572832A
Cited
US4617306A
Cited
US4607041A
Cited
US4562069A
Cited
US4615697A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-04-26 | 1991-10-26 | 1992-04-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-04-26 | 1995-10-26 | 1996-04-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-04-26 | 1999-10-26 | 2000-04-26 | $7700.00 | Window Closed / Lapsed |